AEROSOLIZED TYLOXAPOL IN THE AIRWAYS DISEASE OF CYSTIC FIBROSIS

雾化泰洛沙泊治疗气道囊性纤维化疾病

• 批准号: 6114854
• 负责人: BRUCE C MARSHALL
• 金额: $ 2.81万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6114854
• 关键词: aerosols; bioassay; clinical research; cystic fibrosis; detergents; drug adverse effect; drug screening /evaluation; experimental designs; human subject; particle; volunteer

Characterization of the particle sizes of tyloxapol aerosolized from a nebulizer device and the development of an assay for the measurement of tyloxapol levels in biological fluids are two of the specific aims of the study. Additionally the safety of this drug will be studied in healthy volunteers. Development of study methodology regarding the effectiveness of this agent in cystic fibrosis patients.

泰洛沙泊雾化颗粒尺寸的表征 雾化器装置和测量方法的开发 生物体液中的泰洛沙泊浓度是该项目的两个具体目标 研究。 此外，该药物的安全性将在 健康的志愿者。 开发有关的研究方法 该药物对囊性纤维化患者的有效性。